Form 4: Director Sells ImmunityBio Shares Under 10b5-1 Plan

ImmunityBio Director Barry J. Simon sold 25,000 shares of common stock for approximately $7.88 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Barry J. Simon, a Director at ImmunityBio, Inc. (IBRX), reported a transaction on June 24, 2026.
• He sold 25,000 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on December 18, 2025.
• The weighted average sale price was approximately $7.8763, with individual sales ranging from $7.875 to $7.885.
• Following this transaction, Simon beneficially owns 2,802,788 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-established Rule 10b5-1 plan, mitigating concerns about negative insider sentiment.

Negatives

• Director sale of company stock, which can sometimes be perceived negatively by the market, although executed under a pre-planned trading strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly when executed under a Rule 10b5-1 plan, are common and often intended to diversify personal holdings or meet financial obligations without signaling negative sentiment about the company's prospects. The price range of the sale is also noted.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a director may lead to short-term market perception shifts, though the Rule 10b5-1 plan provides context that it's a pre-planned transaction.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Sale, ImmunityBio, IBRX, Director Transaction, Beneficial Ownership